Chronic Myeloproliferative Disorders Completed Phase 2 Trials for Alemtuzumab (DB00087)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00109993Campath-1H + FK506 and Methylprednisolone for GVHDSupportive Care
NCT00410657Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantSupportive Care